Treatment pattern in patients with idiopathic membranous nephropathy--practices in Sweden at the start of the millennium

Conclusions
Even though the treatment recommendations in idiopathic MN have not changed the last decade, the question of whom and when to treat seems to lead to uncertainty. Recent studies have presented promising results supporting the PLA2R antibody the predictive marker needed for this patient group. The diverse treatment approach presented in this study might have resulted in a worse outcome than expected. Hopefully, unnecessary exposure to immunosuppressive therapy or delayed treatment can be avoided through better support, education and treatment forums, and thus result in an improved outcome.

Source: CKJ: Clinical Kidney Journal - March 15, 2016 Category: Urology & Nephrology Authors: Lonnbro-Widgren, J., Molne, J., Haraldsson, B., Nystrom, J. Tags: GLOMERULONEPHRITIS Source Type: research